A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06270706 · readout ≤ 1,411 d
Sponsored by Pliant Therapeutics, Inc. (industry) · PLRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
124estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-30 | actual | When the study began enrolling |
| Primary completion | Jun 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Solid Tumor
Interventions
- Drug: PLN-101095
- Drug: PLN-101095
- Drug: PLN-101095
- Drug: PLN-101095
- Drug: PLN-101095
- Drug: PLN-101095
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
measured First dose to 35 days
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
measured Day 1 until 16 weeks after end of study treatment regimen
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
measured First dose to disease progression or death from any cause, whichever occurs first.
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
measured First dose to disease progression or death from any cause, whichever occurs first.
Permalink · PLRX's whole pipeline · Catalyst calendar · Every registered study · What changed